Pembrolizumab is a humanised therapeutic antibody against the PD-1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32-year-old man who developed Stevens-Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma (T3N1M1).
No clinical trial protocols linked to this paper
Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.PICO Elements
No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.
Paper Details
MeSH Terms
Associated Data
No associated datasets or code repositories found for this paper.
Related Papers
Related paper suggestions will be available in future updates.